Latest News and Press Releases

Parasol group recommended reduction in proteinuria over 24 months as a surrogate endpoint for full approval of FSGS drugs.

ZyVersa looks forward to meeting with investors and potential collaborators at JPM 2025 to discuss our technology, pipeline, and development milestones.

ZyVersa announces progress toward achieving key near-term development milestones and Q3-2024 financials.

ZyVersa welcomes one-on-one meetings at the HCW Kidney Conference on July 15, 2024.

ZyVersa is on track to achieve key development milestones over the next 3 quarters.

To learn more about ZyVersa's Inflammasome ASC Inhibitor and Renal Pipelines, schedule a one-on-one meeting on 2024 BIO International Conference's Portal.

Key Highlights: Cholesterol Efflux MediatorTM VAR 200 on target to begin Phase 2a clinical trial in patients with diabetic kidney disease H1-2024.Inflammasome ASC Inhibitor IC 100 preclinical program...

Initiation of Phase 2a trial first half 2024 with Cholesterol Efflux Mediator VAR 200 in diabetic kidney disease is a key milestone for ZyVersa.

View ZyVersa Therapeutics' Benzinga All Access Interview To Learn About Key Development Milestones in 2024.

ZyVersa is developing two proprietary product platforms targeting renal and inflammatory diseases. Cholesterol Efflux MediatorTM VAR 200, designed to ameliorate renal lipid accumulation that...